- Home
- CHI vs GHRS Comparison
CHI vs GHRS Comparison
Compare CHI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- GHRS
- Stock Information
- Founded
- CHI 2002
- GHRS 2018
- Country
- CHI United States
- GHRS Ireland
- Employees
- CHI N/A
- GHRS N/A
- Industry
- CHI Investment Managers
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- GHRS Health Care
- Exchange
- CHI Nasdaq
- GHRS Nasdaq
- Market Cap
- CHI 853.5M
- GHRS 774.1M
- IPO Year
- CHI N/A
- GHRS 2021
- Fundamental
- Price
- CHI $11.29
- GHRS $12.54
- Analyst Decision
- CHI
- GHRS Strong Buy
- Analyst Count
- CHI 0
- GHRS 9
- Target Price
- CHI N/A
- GHRS $29.33
- AVG Volume (30 Days)
- CHI 186.2K
- GHRS 269.0K
- Earning Date
- CHI 01-01-0001
- GHRS 11-07-2025
- Dividend Yield
- CHI 9.90%
- GHRS N/A
- EPS Growth
- CHI N/A
- GHRS N/A
- EPS
- CHI N/A
- GHRS N/A
- Revenue
- CHI N/A
- GHRS N/A
- Revenue This Year
- CHI N/A
- GHRS N/A
- Revenue Next Year
- CHI N/A
- GHRS N/A
- P/E Ratio
- CHI N/A
- GHRS N/A
- Revenue Growth
- CHI N/A
- GHRS N/A
- 52 Week Low
- CHI $9.70
- GHRS $6.72
- 52 Week High
- CHI $11.61
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- CHI 60.47
- GHRS 42.79
- Support Level
- CHI $10.86
- GHRS $12.40
- Resistance Level
- CHI $11.50
- GHRS $14.44
- Average True Range (ATR)
- CHI 0.16
- GHRS 0.90
- MACD
- CHI 0.01
- GHRS -0.03
- Stochastic Oscillator
- CHI 69.12
- GHRS 5.60
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.